AstraZeneca (AZN) Withdraws App for Ovarian-Cancer Treatment in Europe
- Top 10 News for 9/26 - 9/30: Deutsche Bank Soars on Settlement; Twitter Back in the M&A Fray; Nike 'Just Didn't Do It' in Q1
- Wall Street rallies, led by Deutsche Bank, financials
- Viacom (VIAB) Forms Special Committee; Will Explore Potential Combination with CBS (CBS)
- Deutsche Bank (DB) Said Near $5.4B Settlement with U.S. - AFP
- Oil up second straight month on OPEC-fueled rally
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
AstraZeneca (NYSE: AZN) is said to have withdrawn its application for approval of cediranib in Europe following a disagreement with regulators.
Bloomberg noted that the action won't affect development of the ovarian cancer treatment.
AstraZeneca filed an application with the European Medicines Agency in June 2015 seeking approval of cediranib for use with platinum-based chemotherapy in adults with a type of ovarian cancer that’s relapsed.
Shares of AstraZeneca are indicated lower Wednesday morning.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AstraZeneca's (AZN) TAGRISSO T790M Companion Diagnostic Test Approved by U.S. FDA
- UBS AG (UBS) volatility elevated on wide share price movement
- Salesforce (CRM) volatility flat into investor day at Dreamforce 2016
Create E-mail Alert Related CategoriesFDA, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!